Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Butyrophilin subfamily 3 member A3 (BTN3A3) is a type I membrane glycoprotein of the immunoglobulin superfamily encoded on human chromosome 6 within the MHC-associated butyrophilin gene cluster. Its ectodomain forms V-shaped homodimers and is structurally homologous to the B7 superfamily; BTN3A-specific antibodies bind distinct epitopes on the IgV domain and can either stimulate or inhibit Vγ9Vδ2 T-cell responses, indicating a role for BTN3A molecules in modulating γδ T-cell activation in infection and cancer contexts. UniProt and InterPro annotate BTN3A3 as playing a role in T-cell responses in adaptive immunity. Wikipedia and NCBI confirm BTN3A3 as the human protein/gene name and locus information.
Agonist anti-BTN3A antibodies can mimic phosphoantigen-mediated activation of Vγ9Vδ2 T cells by binding BTN3A IgV domain epitopes, modulating T-cell activation signaling. Antagonist anti-BTN3A antibodies can inhibit Vγ9Vδ2 T-cell reactivity by binding distinct BTN3A epitopes and blocking activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Butyrophilin subfamily 3 member A3 (BTN3A3).